Clinical Trials
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Latest Clinical Trial Results
ISELIN, N.J., November 19, 2008/PRNewswire-FirstCall/ -- Pharmos Corporation today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 19, 2008 - KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain...
LILLE (France), CAMBRIDGE (Mass.), Nov. 18, 2008 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of...
- Improvements in Motor Function Maintained at Six Months -
- Data to be Presented at 38th Annual Meeting of Society for Neuroscience -
OXFORD, England, Nov. 19, 2008: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today...
TSX: BMR
TORONTO, November 19, 2008 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it will be presenting an...
LONDON, Nov. 19, 2008-AstraZeneca today announced results from three Phase III studies of ZACTIMA (vandetanib) in combination with chemotherapy agents docetaxel (ZODIAC) and pemetrexed (ZEAL) and as monotherapy (ZEST) in non-small cell lung cancer...
HYDERABAD, INDIA (Nov 18, 2008) – Several data presentations from Suven’s portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at Neuroscience 2008 meeting being held at Washington DC, USA during...
AURORA, Ontario, November 19, 2008 /PRNewswire/ -- Helix BioPharma Corp. today announced that it will present preclinical data about the mechanism of action for L-DOS47, the first drug candidate under development based on the Company's...
SAN DIEGO--(BUSINESS WIRE)--Nov 19, 2008 - Results of a new peer-reviewed study published online in the journal Free Radical Biology and Medicine clearly demonstrates that the synergistic impact of the active ingredients used in the formulation of...
NEW YORK--(BUSINESS WIRE)--Nov 19, 2008 - Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active therapies and devices to treat serious illnesses, will present new efficacy data from Phase 1 and 2 clinical trials of...
Company Expects Release of Preliminary Top-line Data from the First Phase III Clinical Trial of JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
PALO ALTO, Calif., November 19, 2008 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc....
SOUTH SAN FRANCISCO, Calif & CAPE TOWN, South Africa--(BUSINESS WIRE)--Nov 19, 2008 - Titan Pharmaceuticals, Inc. (AMEX:TTP) today presented detailed data from its positive Phase 3 placebo controlled study of Probuphine in the treatment of...
Interim Analysis Supports Continuation of GenVec’s PACT Study
Conference Call Scheduled for Today at 9:00AM
GAITHERSBURG, Md., Nov. 19, 2008--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today top-line results of an interim analysis...
Company to Submit NDA for Lead Product, Metgluna™
CAMBRIDGE, Mass., Nov. 19, 2008--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., announced today positive results from a pivotal phase III clinical study of the Company’s oral formulation...
LONDON, November 19, 2008 /PRNewswire-FirstCall/ -- NeuroDiscovery Ltd , a specialty neuroscience service provider and drug development Company, and Sosei Group Corporation , a leading international biopharmaceutical company, today announce that...
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), development-stage oncology and dermatology biopharmaceutical company, announced that the lead investigator for its Phase 2 melanoma study, Professor John F. Thompson,...
PROMETA Reverses GABA Receptor Dysregulation in Methamphetamine Dependent Rats with Increased Anxiety During Withdrawal
LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM), announced today the presentation of data further supporting a...
CAMBRIDGE, Mass., November 18, 2008 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced that 120 data presentations concerning VELCADE research will be featured at the 50th American Society of Hematology (ASH) Annual Meeting in...
Prospective Economic Evaluation of Alternative Antithrombotic Strategies Published in the Journal of the American College of Cardiology
Intended for U.S. Audiences Only
PARSIPPANY, N.J, Nov. 18, 2008--(BUSINESS WIRE)--The Medicines Company (NASDAQ:...
Study failed to meet its primary endpoint
VALLEY COTTAGE, N.Y., November 18, 2008 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic...
More...
